EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ADAM19 Promotes EMT ‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma

Minxin He, Mingrui Li, Yifei Ma, Zhenzhuo Chen, Lingyu Guo, Xiangyu Wang, Wenjing Wang, Tie Chong iD, Zhenlong Wang iD

Cancer Science · 29.10.2026

DOI: 10.1111/cas.70571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 29.10.2026. Verfasst von Minxin He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wu Jieping Medical Foundation Scientific Research Special Project, Key Project of IIT Clinical Research Fund, The Second Affiliated Hospital of Xi‧an Jiaotong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Detection of circulating tumor cells (CTCs), particularly characterization of their epithelial‐mesenchymal transition (EMT) phenotypes, may improve prognostic accuracy for malignancies. Identification of novel biomarkers for CTC classification may improve the characterization of tumor progression and provide potential therapeutic insights for renal cell carcinoma (RCC). Herein, we identified that a disintegrin and metalloproteinase domain‐containing protein 19 (ADAM19) was associated with EMT phenotypes of CTCs. In vitro functional experiments, Western blotting, and RNA sequencing demonstrated that ADAM19 promoted RCC malignant progression and EMT‐related changes and was associated with NOTCH and NF‐κB signaling pathways. Our findings further suggested potential bidirectional association between ADAM19 and these signaling pathways. CTCs isolated from xenograft mouse models exhibited enhanced proliferative, migratory, and invasive abilities, accompanied by increased ADAM19 expression compared with parental tumor cells. Clinical CTC analysis further revealed that ADAM19‐Low‐CTCs were associated with unfavorable clinical outcomes in RCC patients. Notably, higher time‐updated ADAM19‐Low‐CTC counts were identified as an independent risk factor for progression‐free survival (HR = 1.243, 95% CI: 1.006–1.536).

Schlagwörter

Stichwörter der Autor:innen

ADAM19circulating tumor cellsepithelial‐mesenchymal transitionprognostic markerrenal cell carcinoma

Autor:innen und Institutionen

  • Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Department of Pathology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

ORCID-Profile: Tie Chong, Zhenlong Wang

Förderung

  • Wu Jieping Medical Foundation Scientific Research Special Project
  • Key Project of IIT Clinical Research Fund, The Second Affiliated Hospital of Xi‧an Jiaotong University

Zitieren

APA

He, M., Li, M., Ma, Y., Chen, Z., Guo, L., Wang, X., Wang, W., Chong, T., & Wang, Z. (2026). ADAM19 Promotes EMT ‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma. Cancer Science. https://doi.org/10.1111/cas.70571

Vancouver

He M, Li M, Ma Y, Chen Z, Guo L, Wang X, et al. ADAM19 Promotes EMT ‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma. Cancer Science. 2026. doi:10.1111/cas.70571

BibTeX
@article{He2026,
  author = {He, Minxin and Li, Mingrui and Ma, Yifei and Chen, Zhenzhuo and Guo, Lingyu and Wang, Xiangyu and Wang, Wenjing and Chong, Tie and Wang, Zhenlong},
  title = {ADAM19 Promotes EMT ‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70571}
}
Kostenlos starten →